What is Kanjinti™ (trastuzumab-anns)?

Kanjinti™ (trastuzumab-anns) is used to treat certain people with metastatic breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2+). It is used for HER2+ metastatic breast cancer:1-3

  • In combination with paclitaxel as a first-line treatment
  • Alone in people who have received 1 or more chemotherapy drugs for metastatic breast cancer

Metastatic breast cancer is cancer that has spread to other parts of the body, such as the bones or liver. Breast cancer tumors are defined as HER2+ or HER2- cancers. HER2 refers to a specific protein that appears on the surface of cancer cells and makes the cells multiply faster. When cancer cells produce too many HER2 molecules, they are called HER2+ tumors.1-3

Kanjinti is also used to treat certain people with adjuvant breast cancer. Adjuvant therapy attempts to keep cancer from coming back after initial treatment, like surgery.1-3

Kanjinti is a biosimilar to Herceptin® (trastuzumab). Drugs similar in structure to known biologic drugs are called biosimilars.1-3

What are the ingredients in Kanjinti?

The active ingredient in Kanjinti is trastuzumab-anns.2,3

How does Kanjinti work?

Kanjinti is a monoclonal antibody. Antibodies are a normal part of our immune system that act against antigens. These are bacteria, viruses, and other foreign organisms that threaten our health. Monoclonal antibodies are created in a lab to attach to specific antigens on the surface of cancer cells.1-3

Certain breast cancer cells have large numbers of HER2 proteins on their cell surfaces. HER2 proteins stimulate tumors to grow especially fast. By blocking HER2, Kanjinti slows the uncontrolled growth of tumor cells and kills them.1-3

Kanjinti only on tumors with high levels of HER2.  Your doctor will test your tumor for it before prescribing this drug.1-3

What are the possible side effects of Kanjinti?

The most common side effects of Kanjinti include:3

  • Headache
  • Diarrhea
  • Nausea
  • Chills
  • Fever
  • Infection
  • Heart problems
  • Insomnia
  • Cough
  • Rash

Kanjinti has a boxed warning, the strictest warning from the U.S. Food and Drug Administration (FDA). This is because it may cause:3

  • Serious heart problems, including heart failure
  • Severe lung damage
  • Life-threatening reactions to the infusion
  • Serious allergic reactions
  • Worsening of chemotherapy-induced reductions in white blood cells
  • Birth defects in unborn babies

If you have any new or worsening signs of side effects, contact your doctor right away.

These are not all the possible side effects of Kantinji. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Kantinji.

Things to note about Kanjinti

Your doctor will monitor your heart function before and during treatment with Kanjunti.

Before taking Kanjinti, tell your doctor if you:3

  • Are allergic to trastuzumab
  • Have or have had heart disease
  • Have or have had lung disease, a tumor in your lungs, or difficulty breathing
  • Are being treated with radiation therapy to the chest or with other chemotherapy drugs

Kanjinti can harm an unborn baby. If you can become pregnant, you should use birth control during treatment and for some time after the last dose of Kanjinti. You should also not breastfeed during treatment with Kanjinti and for some time after the last dose. Talk to your doctor about your options for birth control and breastfeeding while taking Kanjinti.3

Before beginning treatment for breast cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.

For more information, read the full prescribing information of Kanjinti.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by: Editorial Team | Last reviewed: March 2021